Modality
Gene Editing
MOA
ALKi
Target
KRASG12C
Pathway
Proteasome
PSPET
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
~Apr 2017
→ ~Jul 2018
Phase 2
~Oct 2018
→ ~Jan 2020
Phase 3
Apr 2020
→ Jun 2025
Phase 3Current
NCT07967485
586 pts·ET
2020-04→2025-06·Not yet recruiting
586 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-169mo agoPh3 Readout· ET
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P3
Not yet…
Catalysts
Ph3 Readout
2025-06-16 · 9mo ago
ET
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07967485 | Phase 3 | ET | Not yet recr... | 586 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 |